Abstract-Development of in vitro models by which to study smooth muscle cell (SMC) differentiation has been hindered by some peculiarities intrinsic to these cells, namely their different embryological origins and their ability to undergo phenotypic modulation in cell culture. Although many in vitro models are available for studying SMC differentiation, careful consideration should be taken so that the model chosen fits the questions being posed. In this review, we summarize several well-established in vitro models available to study SMC differentiation from stem cells and outline novel mechanisms recently identified as underlying SMC differentiation programs. (Arterioscler Thromb Vasc Biol. 2011;31:1485-1494.)
A lterations in the normal functions and phenotypic modulation of vascular smooth muscle cells (VSMCs) play major roles in a number of diseases, including atherosclerosis, restenosis, hypertension, and aneurysm. 1 A better understanding of the cellular and molecular mechanisms that control VSMC differentiation is essential to help develop new approaches to both prevent and treat these diseases. Therefore, development of reliable and reproducible in vitro cellular models by which to study smooth muscle cell (SMC) differentiation is needed but has been problematic because of intrinsic peculiarities of SMC.
VSMCs originate from at least 5 different sources of progenitors during embryonic development, including neural crest, proepicardium, serosal mesothelium, secondary heart field and somites. 2, 3 VSMC populations from different embryonic origins are observed in different vessels, as well as within segments of the same vessel, albeit showing sharp boundaries, with no intermixing of cells from different lineages. The relevance of the different embryological origins can be observed in many different aspects of SMC function 2, 3 (see Table 1 ). In addition, SMC responses to environmental signals, such as growth factors, have been observed to vary depending on the developmental origins of SMCs, and these responses are lineage-specific. 2 On the other hand, SMC can undergo phenotypic changes, in vitro and in vivo, switching between secretory and contractile phenotypes, thus obscuring our conceptual reference to terminal differentiation in these cells. Several in vitro models by which to study SMC differentiation from stem cells have become available. 4 -6 Moreover, growing evidence definitely indicates that vascular stem/progenitor cells play a major role in various cardiovascular diseases, including atherosclerosis and angioplasty restenosis. 7 In this review, we summarize current, wellestablished in vitro cellular models available to study SMC differentiation from stem cells according to their developmental origins (see Table 2 and Figure 1 ) and further discuss relevant mechanisms underlying SMC-specific differentiation from stem cells.
Approaches to SMC Differentiation In Vitro:
Embryonic Stem Cell-Based Models
P19 and A404
The P19 cell line was derived from cell cultures established from the primary tumor of a teratocarcinoma that formed on transplantation of a 7.5-day-old mouse embryo into the testis 8, 9 and appear to use mechanisms similar to those of normal embryonic stem cells (ESC) to differentiate. 8 Studies have shown that P19 cells, on treatment with retinoic acid (RA; 10 Ϫ6 mol/L for 48 hours) or dimethyl sulfoxide and 7.5% fetal bovine serum (after 5 to 7 days), differentiate into fibroblast-like cells that express smooth muscle ␣-actin (ACTA2) 10 ; acquire calcium influx features; and respond to phenylephrine, angiotensin II, and endothelin. 11 However, P19 differentiation into SMCs in response to RA is not highly efficient, with a differentiation ratio of less than 1% to 5% (R.S.B., MD, PhD and G.K.O., PhD, unpublished observations, 1995), 6 thus requiring additional enrichment methods to increase the yield of SMCs. 11 Multipotent A404 cells are a P19-derived clonal cell line that has an ACTA2 promoter/intron-driven puromycin resistance gene. 6 When A404 cells are treated with all-trans RA (atRA; 10 Ϫ6 mol/L for 2 days) followed by puromycin (0.5 g/mL for 2 or 5 days), they efficiently differentiate into SMC, with more than 90% of cells expressing ACTA2 and calponin (CNN1) 12 or smooth muscle (SM) myosin heavy chain (MHY11). 6 Additionally, the SMC transcription factor myocardin (MYOCD; an important transcription factor for the regulation of SM-specific genes 13, 14 ) is induced, and only the SM1 isoform of MHY11, a marker of late differentiation, 15, 16 is expressed in this model. A404 cells are an excellent in vitro cellular model by which to study the regulation of SMC-specific genes during the early steps of SMC differentiation. However, it should be kept in mind that the ACTA2 promoter was introduced to select for a small fraction of P19 cells with a higher propensity for SMC differentiation.
Embryoid Body Differentiation System
Embryoid body (EB) cultures were originally used as a method to differentiate embryonic carcinoma cells. 17 EBs are a spontaneously self-assembling 3-dimensional aggregate of pluripotent stem cells grown in vitro in a suspension culture. 18 EBs can form all 3 germ layers and mimic the processes of early embryonic development. 19 Embryonic carcinoma cells, 17 as well as ESC, 19 can form EBs in vitro. Mouse ESCs can be differentiated into SMCs with the EB method. 20 -22 Treatment with atRA (10 Ϫ8 mol/L) and dibutyryl-cAMP (0.5ϫ10 Ϫ3 mol/L) after EBs formed for 6 days leads to spontaneously contracting SM-like cells in 67% of the EBs compared with 10% of the control EBs. 20, 21 These SM-like cells express ACTA2, as well as the vascular MHY11 isoform, and display electrophysiological properties and response to vasoactive agonists, such as angiotensin II, endothelin-1, and KCl, similar to those of VSMCs, indicating that these cells are VSMCs instead of visceral SMCs. 20 One limitation of EB-derived SMCs is that only a fraction of the cells within the EB differentiate into SMC, making it difficult to further analyze the SMCs within EBs. 20, 21 Other strategies have to be applied to enrich SMCs with this system. 22 Moreover, in vivo studies showed that the purified SMCs lead to the formation of teratomas when selected with puromycin for short periods before implantation in mice. Longer puromycin selection times eliminated the formation of teratomas, yet the SMCs were not able to form blood vessels in vivo. 22 Human ESCs can also be differentiated into SMCs by the EB method. 23, 24 Isolated CD34ϩ vascular progenitor cells could differentiate into SM-like cells when treated with platelet-derived growth factor-BB (PDGF-BB; 50 ng/mL for 3 passages) and showed a spindle-shaped morphology. Meanwhile, the cells that expressed the SM marker genes ACTA2, MHY11, SM22␣ (TAGLN), CNN1, and caldesmon and were able to contract in response to carbachol. 23 However, it is important to note that these cells also expressed the endothelial markers angiopoietin-2 and Tie2, implying that the SMC differentiation process was incomplete. Interestingly, subcutaneous injection of a mixture of endothelial cell-like and SMC-like cells isolated from human EBs into nude mice showed that these cells could form human microvessels in vivo. 23 Our group used an alternative approach to differentiate SMCs from EBs derived from human ESCs. In this method, outgrowth from EBs was isolated and differentiated into SMCs using smooth muscle growth medium in combi- 24 Further analysis of the SMCs derived from human EBs showed that they contracted in response to carbachol and KCl treatment, indicating that the SMCs were functional. 24 One of the major advantages of the EB method is that it mimics the processes observed during early embryonic development, including the expression of essential regulatory molecules occurring in the same time course as observed during embryogenesis. 19, 25 Additionally, it is possible to use genetically manipulated ESCs to study genes that lead to embryonic lethality in vivo. 18 Therefore, EBs allow for a unique opportunity to study molecular mechanisms of SMC differentiation in an environment that recapitulates early embryonic processes, but in vitro. On the other hand, there are also limitations with this method. First, differentiation methods that rely on the addition of soluble factors to the culture medium have the disadvantage that only the cells on the exterior of the EB are in direct contact with the medium, and the cells within the EBs will not be exposed to the soluble factors. 18 Second, many cell types are present within the EBs, and methods to separate SMCs from other cell types are needed. 22 Finally, heterogeneity within EBs and between EBs occurs because of a lack of axial specification or patterning during differentiation. 18, 26 
ESC Adherent Monolayer Culture Differentiation System
ESCs and induced pluripotent stem cells have been successfully differentiated into SMCs using an adherent monolayer culture differentiation system. 27, 28 In this model, ESCs are separated from the feeder mouse embryonic fibroblasts and cultured in a monolayer in the presence of atRA (10 Ϫ5 mol/L), leading to their differentiation into SMCs at an efficiency of 41% to 65% for MHY11 expression. 27, 28 Morphological change into a SMC-like phenotype is accompanied by the expression of SM marker genes (ACTA2, TAGLN, CNN1, and MHY11) 27, 28 and characteristics of functional SMCs, including (1) contraction in response to the muscarinic agonist carbachol, 27, 28 (2) autonomous SM-like contraction frequency after prolonged culture, 27 and (3) functional calcium responses to the vasoconstrictors caffeine, endothelin, and the depolarizing agent KCl. 28 ESC single-layer culture plus stem cell antigen-1-positive cell selection with a collagen IV-based differentiation model also showed the advantage of a single-layer culture strategy. 29, 30 With this model, sorted stem cell antigen-1-positive cells differentiated toward SMCs 29 and endothelial cells. 30 A highly purified SMCs population (Ͼ95%) expressing high levels of SMC markers could be achieved after 30 days of continued culture. 29 Unlike in EBs, in monolayer models, individual ESCs are equally exposed to stimuli, leading to fairly homogeneous and high-yield differentiation. It can be used with different types of ESCs [27] [28] [29] for the study of early events in their differentiation into SMC differentiation. However, because this differentiation strategy is not 3-dimensional (as embryogenesis is), the spatial gene regulation cues regarding SMC differentiation will be missed. Although ESCs provide a great model for studying early stages of development, when these cells are induced to differentiate into a specific lineage, it is unknown whether certain intermediate lineages are skipped, and thus the potential effects of skipping these steps on the differentiation process are not known. This method also works with induced pluripotent stem cells, 28 providing a unique chance to generate SMC in vitro from induced pluripotent stem cells isolated from individual patients with diseases resulting from genetic deficient SMCs. Genetic correction of SMCs in vitro or their modulation could be the basis for future cell-and tissue-based therapy.
Mesoderm-Derived Models C3H/10T1/2 Cells
The 10T1/2 cell line was established from 14-to 17-day-old whole C3H mouse embryos. 31 C3H/10T1/2 cells can differentiate into SMCs by being cocultured with endothelial cells 
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or treated with transforming growth factor-␤1 (TGF-␤1, 1 ng/mL) for 24 to 48 hours, evidenced by a phenotypic change from a polygonal into a spindled-shaped phenotype, accompanied by the expression of SM-specific markers (ACTA2, MHY11, CNN1, and TAGLN). 4 This model is very attractive for the study of SMC differentiation because of (1) availability for purchase of the cells from the American Type Culture Collection, (2) undemanding culture conditions, and (3) easy and quick differentiation using TGF-␤1, allowing for fast results. Nonetheless, it has been suggested that 10T1/2 cells cannot fully differentiate into SMCs on TGF-␤1 treatment but rather to myofibroblasts 3 that do not express MYOCD and showing inconsistency in MHY11 expression. 4, 14, 32 These conflicting reports on expression of SM markers in this model are likely due to differences in the culturing methods and manipulation of these cells in different laboratories. Despite these caveats, this model is still widely used as a quick method in gain-and loss-of-function studies and to determine whether certain regulatory molecules can induce SMC differentiation.
Neural Crest Stem Cell-Derived Models

Monc-1 Cells
Monc-1 is an immortalized neural crest cell line that was generated by retroviral transfection of a primary culture of mouse neural crest cells with the v-myc gene. 33 Two in vitro SMC differentiation models use Monc-1 cells: (1) with 10% fetal bovine serum 5 and (2) with TGF-␤ (5 ng/mL for 3 days), 34 both resulting in induction of expression of SM markers, 5, 34 including the MHY11 and smoothelin markers of SMCs at a highly differentiated stage. 15, 35, 36 However, SMCs derived from serum-treated Monc-1 cells displayed a flattened morphology, similar to the synthetic phenotype of SMC; they lack response to carbachol 5, 34 ; and expression of the epithelial marker E-cadherin was not completely eliminated, 34 suggesting only a partial epithelial to mesenchymal transformation. In contrast, SMCs derived from TGF-␤1 treatment of Monc-1 cells had an elongated spindle-shaped morphology, 34 characteristic of the contractile state of SMC, and they contracted in response to carbachol and lost expression of E-cadherin, 34 indicating that TGF-␤ treatment of Mon-1 cells seems to be a better model for studying differentiation from a neural crest lineage into functional SMCs.
Although they are a rapid and reproducible model resulting in the expression of multiple SM markers, including MHY11 and smoothelin, Monc-1 cells have to be kept in a chemically defined medium, referred to as complete medium, that is quite complicated to prepare, to retain their undifferentiated state. 5, 34, 37 Although a very attractive method by which to study the differentiation of neural crest-derived SMCs in vitro, limited follow-up studies are available to define the Monc-1 as a bona fide SMC differentiation system. Thus, for instance, Monc-1 cells were immortalized by constitutive expression of myc. 33, 38 The differentiation program in Monc-1 cells did not seem to be overtly disturbed by the constitutive expression of v-myc, based on the observations that Monc-1 cells could differentiate into neurons, glia, melanocytes, and SMCs. 5, 33, 34 However, the potential effects of v-myc constitutive expression during differentiation on the molecular and cellular processes of the SMC differentiation program remain to be addressed.
JoMa1 Cells
The JoMa1 cells are immortalized neural crest stem cells that were derived from neural crest primary cultures from a transgenic mouse line harboring conditional tamoxifeninducible expression of c-myc. Withdrawal of tamoxifen from the culture medium, resulting in loss of c-myc expression, and treatment of the JoMa1 cells with TGF-␤ (1 ng/mL for 6 days) induce differentiation into SMCs, as indicated by morphology change and expression of ACTA2 (90% of cells), SM ␥-actin, and low levels of CNN1. 38 A clonally derived subline of JoMa1, termed JoMa1.3, showed a more pure SMC lineage expressing higher levels of CNN1 than its parental line on TGF-␤1 treatment. 38 Unlike in Monc-1 cells, in JoMa1 and JoMa1.3 cells, expression of c-myc subsides when these cells are induced to differentiate into SMCs, 38 therefore avoiding potential problems from the interference of this oncogene with the differentiation program. In that regard, induction of differentiation in the presence of tamoxifen, which maintains expression of c-myc in JoMa1 and JoMa1.3 cells, leads to cell death, showing incompatibility between the proliferation and differentiation signals in this cell background. 38 Although it is an emerging attractive method by which to study SMC differentiation from a neural crest lineage, JoMa1 presents disadvantages similar to those of the Monc-1 system in that it requires a chemically defined medium to keep the cells in an undifferentiated state, and additional follow-up studies may be required to further establish this method.
In summary, a variety of in vitro cellular models are currently available by which to study SMC differentiation. Careful consideration should be given to their relative advantages and their intrinsic limitations to select the model that best suits the experimental questions being posed.
Mechanisms That Control SMC Differentiation In Vitro
SMC differentiation from stem cells is a complex and, at least so far, poorly defined process. Accumulating evidence from the different stem cell-SMC differentiation systems has revealed that a delicately coordinated molecular network orchestrates the program of SMC differentiation from stem cells (Figure 2 ). Numerous layers of regulation (eg, epigenetic modifications, gene transcription and translation, posttranscription and posttranslation) and various signaling pathways and molecules, such as MYOCD-serum response factor (SRF) complex, extracellular matrix (ECM), 39 retinoid receptor, TGF family (eg, mothers against decapentaplegic homolog 3 21,40 ), Notch family, 41 reactive oxygen species (eg, NADPH oxidase 4 42 and NRF3 43 ), and others (eg, paired-like homeodomain 2 44 and protein inhibitor of activated STAT-1 45 ), play major roles in SMC differentiation from stem cells. The present review does not cover all recognized aspects of the mechanisms regulating SMC differentiation at large but instead focuses on the recent progress in the specific field of stem cell differentiation into SMC.
Retinoid Signaling
RA is a metabolite of vitamin A and 1 of the most important regulatory factors of gene transcription. 46 atRA binds to retinoic acid receptor (RAR; RAR␣, RAR␤, or RAR␥) in the nucleus, which, in turn, can bind to 1 of the retinoid X receptors (RXRs; RXR␣, RXR␤, or RXR␥), and the RXR/ RAR heterodimer complex binds to DNA and leads to the activation of RA responsive genes. 47 At certain RAresponsive genes, the RXR/RAR complex binds to highly compacted, higher-order chromatin, allowing RNA polymerase II and other general transcription factors to activate transcription 48 and leading to cell lineage-specific, epigenetic modifications at those genes. 49, 50 Studies on the effects of retinoids on vasculogenesis have indicated that low or absent levels of atRA have profound consequences for normal Proposed model for the regulation of SMC-specific genes during ESC/SMC differentiation and phenotypic switching. A, In undifferentiated ESCs, Oct4, Sox2, Nanog, and Klf4 form a core transcription complex maintaining the pluripotent network for stem cell self-renewal. Downstream genes associated with stem cell proliferation and pluripotency are actively transcribed marked with histone 3 lysine 4 methylation (H3K4me) and histone acetylation. Meanwhile, target genes cooccupied by the core transcription complex and encoding SMC-specific genes are transcriptionally silent, marked with H3K27me associated with the recruitment of HDACs and corepressors at the regulatory regions of these SMC-specific genes. As a result, the regulatory DNA sequences of these SMC-specific genes are wrapped in compacted chromatin and block the access from the MYOCD-SRF complex and subsequent activation. B, SMC differentiation from ESCs has been shown to be mediated by multiple mechanisms. Extracellular stimuli (including retinoid acid and various growth factors) initiate the permanent shutdown of activation of the pluripotent core transcription complex on pluripotent genes and lead to downstream domino cascades. Ultimately, these serial programs result in dramatic chromatin modification in these regions, marked by histone acetylation and H3K4me, and release the compacted chromatin containing the regulatory domain of SMC-specific genes to expose the regulatory domains to diverse activator networks, including transcription factors, reactive oxygen species, miRNAs, and nuclear receptors. The transcription of most SMC-specific genes is mainly activated by SRF binding to CArG boxes located within the regulatory regions of SMC-specific genes, enhanced by MYOCD. Additional elements further enhance transcription, such as bHLH transcription factors via PIAS-1 and the TGF-␤ control element via SMAD3. C, SMC phenotypic switching is initiated by various extracellular cues. During this process, transcription of SMC-specific markers is downregulated, and SMCs undergo the phenotypic transformation from contractile to proliferative/synthetic status. The regulatory networks involved into this change include histone modification, which reprograms to deacetylation and H3K27me, further closing active chromatin; phosphorylation-ELK-1 by ERK1/2, thereby blocking MYOCD interactions with SRF; KLF4 and HeyL blocking SRF binding to CArG boxes; and microRNA interference operating posttranscriptionally on critical regulators. Oct4 indicates octamer-binding protein 4; Sox2, SRY-box containing gene 2; HATs, histone acetyltransferases; HMTs, histone methylation transferases; GCNF, germ cell nuclear factor; Pitx2, paired-like homeodomain 2; Nkx2.5, NK2 transcription factor related, locus 5; SRF, serum response factor; NOX4, NADPH oxidase 4; PIAS-1, protein inhibitor of activated STAT-1; Pol II, polymerase II; ELK-1, ETS domain-containing protein 1; ERK, extracellular signal-regulated kinase; NK, Nirenberg-Kim; HeyL, hairy/enhancer-of-split related with YRPW motif-like; SMAD3, mothers against decapentaplegic homolog 3; Msx, musclesegment homeobox like protein; TCE, TGF-␤ control element. bHLH, basic helix-loop-helix; RA, retinoid acid; BMP4, bone morphogenetic protein 4; ROS, reactive oxygen species; Me, methylation; Ac, acetylation; SUMO, sumoylation.
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vascular development. 46 A strong RA response signal was predominantly detected in the developing ductus arteriosus, and the signal colocalized with the expression of the adultspecific MHY11 isoform SM2. 51 Direct evidence implicating atRA in vasculogenesis is offered from studies in retinoid receptor knockout mice, although not every single-retinoid receptor-null mice showed vasculogenesis deficiency, partially because of generalized growth deficiency (as in RAR␣ -/-or RAR␥ -/-) and possible functional compensation by other retinoid receptors. [52] [53] [54] As indicated in the earlier sections of this review, a number of in vitro studies have shown that atRA positively influences the SMC differentiation program from stem cells. In the P19 embryonic cell model system of SMC differentiation, atRA was shown to stimulate several SMC markers, including ACTA2 and MHY11, 11, 55, 56 and the expression of MHox, 11 a homeodomain-containing transcription factor that potentiates the expression of ACTA2. An elevation in the expression of ACTA2 and MHY11 was also observed in atRA-treated ESCs. 20, 28 Our studies have shown that atRA triggers microRNA (miR)-10a and miR-1 expression in ESCs and subsequently represses histone deacetylase 4 (HDAC4) and Krü ppel-like factor 4 (KLF4), respectively, and leads to SMC differentiation. 57, 58 On the other hand, the presence of atRA dramatically increased the frequency of contracting SMCs from ESCs. 20 These data suggest an important positive role for atRA in the SMC differentiation from stem cells.
Epigenetics and HDAC Signaling
Several studies indicate that ESCs are characterized by compact chromatin and less transcription activity compared with differentiated cells. As differentiation advances, chromatin changes to a repressed and inactive state. 59 Specific residues in the N-terminal tails of histones are prone to numerous reversible posttranslational modifications, including acetylation, methylation, phosphorylation, 60 and proteolysis. 61 These modifications are achieved via different chromatin modifying enzyme complexes with opposing functions, which are responsible for the dynamic behavior of chromatin and include histone acetyltransferases, HDACs, DNA methyltransferases, 62 and histone demethylases. 63 Recent studies suggest that a "histone bivalent" model (active and inactive histone modifications) regulates ESC status by controlling gene expression for lineage-specific genes, which are silent in pluripotent ESCs, but may be expressed on differentiation. 64 -67 The suppressive modifications (histone 3 lysine 27 methylation [H3K27me3]) and activating marks (H3K4me3 and histone 3 lysine 9 tri-acetylation) in various cell lineagespecific gene promoters have been identified in differentiation. 66, 67 This model implies that the key developmental control genes are present in a primed or poised status in ESCs, as defined by opposite combinations of histone alterations to help maintain pluripotency and suppress developmental gene expression. 66, 67 This primed or poised epigenetics status must be eliminated in pluripotent stem cells to trigger early development, and later within tissuespecific differentiation. It remains unknown exactly how these cues operate in different cell types.
The latest and most detailed descriptions regarding the relationship between epigenetics and SMC differentiation come mostly from studies of SMC phenotypic switch. 68 However, it could be proposed that a similar mechanism could be at play in regulating ESC differentiation into SMCs (Figure 2 ). MYOCD is a critical SMC-specific coactivator of SRF, which forms a dimer and binds to the CArG element located within SMC-specific genes. 13, 69 The ability and stability of MYOCD-SRF complex binding to regulatory sequence of SMC-specific genes substantially controls SMCspecific gene expression. 68 Several epigenetic components have been shown to affect SMC differentiation by changing the association between MYOCD-SRF complex and regulatory DNA sequence. 70 -72 Among these, HDAC7 was shown to undergo alternative splicing during SMC differentiation from ESCs and lead to the enhancement of the binding between SRF dimer and MYOCD. As a result, MYOCD-SRF complex was recruited to the TAGLN promoter and activated SMC marker gene expression. 73 At the same time, studies have suggested that the modification of histone features of chromatin containing SMC genes, in response to extracellular cues, in parallel alters the accessibility of MYOCD-SRF complex to the DNA sequence of SMC-specific genes. 68, 72, 74 For instance, the status of SMC-specific H3K4Me2 and H4 acetylation at CArG boxes is dynamically regulated, corresponding to PDGF-BB treatment. 68 HDAC p300 can associate with the transcription activation domain of MYOCD and induce the expression of SMC genes, whereas HDAC5 suppress the expression of SMC genes through interaction with different domains of MYOCD. 75 Moreover, the interaction of KLF4, E-twenty-six domain-containing protein 1, and HDACs, which together mediate the regulation of the SMCspecific gene expression, has been demonstrated. 74 This interaction was accompanied by hypoacetylation of histone H4 at the ACTA2 promoter via recruitment of HDAC2 and HDAC5. 74 These intricate interactions provide harmonized regulatory control over the SMC phenotype, along with diverse environments. 68 Although it is known that HDACs play roles in the differentiation of stem cells toward SMCs, 76 additional studies will be required to determine the relationships between histone (de)acetylation and SMC differentiation modulators in the stem cell/SMC differentiation system.
ECM Signaling
Differentiation and cell fate decisions are controlled by their surrounding microenvironment, named the stem cell niche. 77 Stem cell niches are anatomically localized in protected sites of tissues and regulate cell adherence, growth, migration, apoptosis, and differentiation via external signals. 77, 78 The ECM, one component of niches, provides a chemical and mechanical structure that is essential for development and for responses to physiological/pathophysiological signals. 79 The ECM structure is dictated by the interaction of collagen fibers with each other and with laminin, as well as highmolecular-weight proteoglycans. Furthermore, studies have proven that ECM can modulate the bioactivities of growth factors and cytokines, such as TGF-␤, tumor necrosis factor-␣, and PDGF. 78 In addition to the structural stability provided by the cell-secreted ECM constituents, cells residing in the ECM can influence ECM signaling by producing enzymes that cause proteolytic modification of proteins and growth factors in the ECM. 80 Previous studies have demonstrated that the 3-dimensional collagen matrix mimicked such a 3-dimensional tissue structure in vitro and induced ESCs to differentiate into various cell lineages. 81 Collagen IV has been used as a coating medium to promote vascular progenitor cell differentiation into SMCs in the presence of serum, as well as a feeder cell layer with the addition of vascular endothelial growth factor or PDGF. 82, 83 Additional studies determined that collagen IV coating facilitated and enriched the differentiation of stem cell antigen-1-positive vascular progenitor cells from ESCs. 29 Our group recently developed nanofibrous poly-Llactide scaffolds and found that tubular nanofibrous poly-Llactide scaffold preferentially supported contractile phenotype of human aorta SMCs under in vitro culture conditions, as evidenced by elevated gene expression levels of SMCs contractile markers including MHY11, smoothelin, and MYOCD. In vivo subcutaneous implantation studies confirmed human aorta SMC differentiation in the implants. 82 These observations revealed that both ECM is essential during embryonic SMC differentiation.
MicroRNA Signaling
MicroRNA is a class of highly conserved, single-stranded, noncoding small RNAs proven to be involved into widespread cellular functions, such as differentiation, proliferation, migration, and apoptosis. 84, 85 Mature miRNAs associate with a nuclease complex to target mRNAs for the purpose of mediating mRNA silencing primarily through their degradation through Argonaute-catalyzed mRNA cleavage, as emerging evidence indicates, 86, 87 and translational repression. 84, 88 Our group has found that miRNAs underwent dynamic changes during the differentiation process from ESCs to SMCs. 57, 58 Among those, miR-1 and miR-10a showed upregulation, and blockade with anti-miR-1 or anti-miR-10a repressed SMC differentiation, evidenced by a significantly reduced VSMC differentiation percentage. Furthermore, individual duplexes between miRNA and potential targets were identified for miR-1:KLF4 and miR-10a:HDAC4. 57, 58 Interestingly, miR-10a activity was regulated by nuclear factor-B in this model of SMC differentiation from ESCs. This result suggests that miRNAs play a critical role to regulate SMC differentiation from ESCs in vitro. 57, 58 Additionally, after the miR-143/145 cluster was found to be 1 of the regulators involved with SMC phenotypic switch, 89 this cluster has been shown to regulate SMC differentiation from stem cells/ progenitor. 90 -93 Deletion of miR-145 impaired the conversion from fibroblasts to VSMCs induced by MYOCD and repressed expression of the SMC contractile apparatus. In addition, overexpression of miR-145 enhanced differentiation of JoMa1.3 cells into the VSMC lineage. 90 The number of contractile VSMCs significantly decreased, and the number of synthetic VSMCs increased remarkably in the aorta and the femoral artery in miR-143/145 double knockout mice, while, simultaneously, the number of noncontractile, proliferating precursors increased. [91] [92] [93] Furthermore, VSMCs within miR-143/145 double mutant artery showed a significant inhibition in the expression of SMC-specific differentiation markers. 91, 92 Direct evidence that miRNAs are fundamental regulators of VSMC differentiation came from the study of a mouse conditional knockout of the rate-limiting enzyme Dicer in VSMCs of blood vessels that results in late embryonic lethality at embryonic day 16 to 17. 94 Loss of VSMC Dicer results in dilated, thin-walled blood vessels, which may be due to a reduction in cellular proliferation. Moreover, the resultant VSMCs exhibited loss of contractile apparatus and ensuing impaired contractility, which could be partially rescued by overexpression of miR-145 or MYOCD. 94 This study further supports the idea that Dicer-dependent miRNAs are essential for VSMC development and function by regulating differentiation and indicates that miRNAs play critical roles in maintaining the differentiated phenotype of VSMCs.
Perspectives
Understanding the detailed mechanisms of stem cell differentiation into SMCs is essential not only for elucidating basic aspects of vascular biology but also for exploring clinical therapeutic methods. Although a variety of in vitro cellular models are available to study detailed mechanisms of SMC differentiation, there are 2 important considerations that should be taken into account when deciding which experimental system to use. First, there are a variety of embryonic origins of SMCs, as discussed above. Thus, it is proposed that individual regulatory regimes regarding differentiation control may exist in SMCs of disparate embryonic origin, and therefore, the choice of cellular models to address the specific ideas may make a significant difference. Second, the intrinsic limitations of in vitro culture of SMCs should be taken into consideration. It is important to keep in mind that it is not known to what extent in vitro differentiation models recapitulate SMC differentiation and maturation in vivo. Therefore, although in vitro models are a very powerful and complementary tool to provide insights into the molecular mechanisms of SMC differentiation in a controlled environment, in vivo experiments are needed to support the findings from the various in vitro models.
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